1-methyl-4-phenylpyridinium has been researched along with Parkinson Disease, Secondary in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (20.62) | 18.7374 |
| 1990's | 29 (29.90) | 18.2507 |
| 2000's | 19 (19.59) | 29.6817 |
| 2010's | 28 (28.87) | 24.3611 |
| 2020's | 1 (1.03) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Duan, Q; Gao, Y; He, P; Huang, H; Huang, R; Ma, G; Nie, K; Wang, L; Zhang, J; Zhang, Q; Zhang, Y | 1 |
| Huang, Q; Xu, M; Zhu, X | 1 |
| Hu, C; Huang, J; Lai, W; Leng, F; Li, G; Liu, W; Liu, Y; Sheng, F; Tang, Q; Wang, Q; Zhang, Q; Zhang, R; Zhou, M | 1 |
| Chang, KH; Chen, CM; Chen, YJ; Lee-Chen, GJ; Lin, JL; Lo, YS; Wei, PC; Wu, YR; Yao, CF | 1 |
| Gu, X; Liu, L; Shen, Q; Xing, D | 1 |
| Go, S; Hozumi, I; Inden, M; Kambe, T; Kurita, H; Yokoo, K | 1 |
| Capps, J; Virga, DM; Vohra, BPS | 1 |
| Kotake, Y | 1 |
| Lee, JC; Moon, MH; Yang, JS | 1 |
| Ekpo, OE; Enogieru, AB; Haylett, WL; Hiss, DC; Miller, HC; van der Westhuizen, FH | 1 |
| Bernstein, AI; O'Malley, KL | 1 |
| Anantharam, V; Ghosh, A; Harischandra, DS; Jin, H; Kanthasamy, A; Kanthasamy, AG; Qian, Z; Rana, A; Saminathan, H; Sondarva, G | 1 |
| Chen, T; Dai, SH; Fei, Z; Jiang, XF; Liu, W; Luo, P; Yang, YF; Zheng, XR | 1 |
| Yin, M; Zhang, MH; Zhang, XM | 1 |
| Chae, YJ; Chaudhuri, AD; Choi, DC; Jain, MR; Junn, E; Kabaria, S; Li, H; Mouradian, MM | 1 |
| Chan, HM; Figeys, D; Mailloux, R; Ning, Z; Shao, Y | 1 |
| Andrade, PB; Guedes-Dias, P; Leitão-Rocha, A; Oliveira, JM; Pinho, BR; Quintas, C; Reis, SD; Santos, MM; Valentão, P | 1 |
| Gomolin, I; Jeitner, TM; Kalogiannis, M; Krasnikov, BF; Moran, GR; Peltier, MR | 1 |
| Jiao, Y; Le, T; Wang, J; Wei, R | 1 |
| Kotake, Y; Miyara, M; Ohta, S; Sanoh, S; Tokunaga, W | 1 |
| Ascenzi, P; Beltrami, AP; Bertuzzi, M; Cesselli, D; Codrich, M; Espinoza, S; Francescatto, M; Giacca, M; Gustincich, S; Leanza, G; Persichetti, F; Russo, R; Zentilin, L; Zucchelli, S | 1 |
| Fu, WM; Hung, SY; Kang, KH; Liou, HC; Wen, CC; Wu, RM | 1 |
| Chen, J; Chen, YZ; Huang, JZ; Liu, CF; Su, M; Yang, YP; Zheng, HF | 1 |
| El Bahh, B; Luchtman, DW; Meng, Q; Song, C; Yang, J; Zidichouski, JA | 1 |
| Chien, WL; Fu, WM; Hung, SY; Kang, KH; Lee, MJ; Lee, TR | 1 |
| Ka, M; Kook, YH; Um, M | 1 |
| Ahn, EH; Cho, SW; Choi, SY; Eum, WS; Hwang, JH; Jeong, HJ; Kang, HW; Kang, TC; Kim, DS; Kim, DW; Kim, MJ; Kwon, OS; Lee, YP; Park, J; Shin, MJ; Sohn, EJ | 1 |
| Chen, R; Huang, J; Liu, K; Shen, L; Sun, X; Yang, J; Zhang, T | 1 |
| Bähr, M; Frank, T; Koch, JC; Lingor, P; Saal, KA; Szego, ÉM; Tatenhorst, L; Tönges, L; Weishaupt, JH | 1 |
| Liu, Q; Peng, J; Rao, MS; Zeng, X | 1 |
| Cory-Slechta, DA; Di Monte, DA; Langston, JW; Manning-Bog, AB; McCormack, AL; Thiffault, C; Thiruchelvam, M | 1 |
| Holtz, WA; O'Malley, KL | 1 |
| Kotake, Y; Ohta, S | 1 |
| Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A | 1 |
| Cappelletti, G; Maci, R; Surrey, T | 1 |
| Acuña-Castroviejo, D; Alvira, D; Camins, A; Folch, J; Pallas, M; Tajes, M; Verdaguer, E | 1 |
| German, DC; Liang, CL; Manzino, L; Sonsalla, PK; Yazdani, U; Zeevalk, GD | 1 |
| Davis, RW; Doostzadeh, J; Giaever, GN; Langston, JW; Nislow, C | 1 |
| Irwin, I; Langston, EB; Langston, JW | 1 |
| Itano, Y; Kitamura, Y; Nomura, Y | 2 |
| Ambrosio, S; Bartrons, R; Bendahan, G; Calopa, M; Espino, A | 1 |
| Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM | 1 |
| Lange, KW; Riederer, P | 1 |
| Atadzhanov, MA; Basharova, LA; Kryzanovskiĭ, GN; Magaeva, SV; Trekova, NA; Vetrilé, LA | 1 |
| Atadzhanov, MA; Kryzhanovskiĭ, GN; Nerobkova, LN; Voronina, TA | 1 |
| Griffiths, HR; Lunec, J; Willets, JM; Williams, AC | 1 |
| Caron, MG; Giros, B; Pifl, C | 1 |
| McCrodden, JM; Sullivan, JP; Tipton, KF | 1 |
| Hou, JG; Lin, LF; Mytilineou, C | 1 |
| Basharova, LA; Evseev, VA; Kryzhanovskiĭ, GN; Trekova, NA; Vetrilé, LA | 1 |
| Dunigan, CD; Shamoo, AE | 1 |
| Olanow, CW | 1 |
| Samuelsson, EB; Sundström, E | 1 |
| Edwards, RH; German, DC; Liang, CL; Sonsalla, PK; Speciale, SG | 1 |
| Bennett, JP; Cassarino, DS; Fall, CP; Smith, TS | 1 |
| Akutsu, S; Fukushima, S; Hayase, N; Igarashi, K; Kimura, K; Matsubara, K; Naoi, M; Ohta, S; Ohtaki, K; Senda, T; Uezono, T; Yamashita, Y | 1 |
| Bales, KR; Carvey, PM; Dodel, RC; Du, Y; Ling, Z; Paul, SM | 1 |
| Ohta, S; Yamakawa, T | 1 |
| Dawson, TM; Dawson, VL; Guastella, DB; Hoffman, BE; Jackson-Lewis, V; Mandir, AS; Przedborski, S; Simbulan-Rosenthal, CM; Smulson, ME; Wang, ZQ | 1 |
| Obata, T | 1 |
| Hamasaki, N; Kang, D; Muta, T; Ohsato, T; Takamatsu, C; Umeda, S | 1 |
| Burkhardt, K; Kaftan, A; Schwarz, J; Storch, A | 1 |
| Aomine, M; Obata, T; Yamanaka, Y | 1 |
| Ambrosio, S; Bermúdez, J; Boada, J; Cutillas, B; Roig, T | 1 |
| Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S | 1 |
| Disshon, KA; Dluzen, DE | 1 |
| Absi, E; Ayala, A; Machado, A; Parrado, J | 1 |
| Chun, HS; DeGiorgio, LA; Gibson, GE; Kidd, VJ; Son, JH; Zhang, H | 1 |
| Kubota, S; Obata, T; Yamanaka, Y | 1 |
| Fukuhara, Y; Ishitani, R; Kashiwaya, Y; Nakashima, K; Shimoda, K; Takeshima, T | 1 |
| Corsini, GU; Fascetti, F; Fornai, F; Oberto, G; Vaglini, F; Zuddas, A | 1 |
| Basma, A; Geller, HM; Heikkila, RE; Nicklas, WJ; Saporito, M | 1 |
| Kitayama, S; Shimada, S; Uhl, GR | 1 |
| Fang, J; Gorrod, JW | 1 |
| Nagatsu, T | 1 |
| Dunnett, SB; Morris, BJ; Northrop, AJ; Sirinathsinghji, DJ | 1 |
| Bachurin, SO; Dranyĭ, OA; Kalashnikov, VV; Lermontova, NN; Petrova, LN; Serkova, TP; Soliakov, LS; Tkachenko, SE | 1 |
| Bradbury, AJ; Costall, B; Jenner, PG; Kelly, ME; Marsden, CD; Naylor, RJ | 1 |
| Beale, AM; Castagnoli, N; Gee, SJ; Gunther, R; Hammock, BD; Higgins, RJ; Shinka, T; Work, T | 1 |
| Chiueh, CC; Liang, CM; Liang, SM | 1 |
| Atadzhanov, MA; Kucherianu, VG; Nikushkin, EV; Sharkova, LM; Zagorevskiĭ, VA | 1 |
| Atadzhanov, MA; Kryzhanovski?, GN; Nerobkova, LN; Voronina, TA; Zagorevski, VA | 1 |
| Brücke, T; Riederer, P | 1 |
| Frei, B; Richter, C | 1 |
| Poirier, J | 1 |
| Beresford, IJ; Hall, MD; Heavens, RP; Richards, SJ; Sirinathsinghji, DJ | 1 |
| Beresford, IJ; Davenport, AP; Hall, MD; Hill, RG; Hughes, J; Sirinathsinghji, DJ | 1 |
| Kopin, IJ | 2 |
| Nakamura, S; Vincent, SR | 1 |
| Chacon, JN; Chedekel, MR; Land, EJ; Truscott, TG | 1 |
| Castagnoli, N; Ramsay, RR; Singer, TP; Trevor, AJ | 1 |
| Barbeau, A; Boyer, H; Buu, NT; Dallaire, L; de Lanney, LE; Irwin, I; Langston, EB; Langston, JW; Veilleux, F | 1 |
| Barbeau, A; Buu, NT; Dallaire, L; Poirier, J; Rucinska, E | 1 |
| Barbeau, A; Poirier, J | 1 |
| Lewin, R | 1 |
7 review(s) available for 1-methyl-4-phenylpyridinium and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Neurotoxicity Mechanism of Environmental Chemicals and Its Evaluation System].
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Environmental Exposure; Environmental Health; Environmental Pollutants; Gene Expression; Hazardous Substances; Humans; Neurons; Parkinson Disease, Secondary; Receptors, AMPA; Tetrahydroisoquinolines; Trialkyltin Compounds | 2018 |
MPP+ analogs acting on mitochondria and inducing neuro-degeneration.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Electron Transport; Humans; Isoquinolines; Mitochondria; Neurodegenerative Diseases; Neurons; Parkinson Disease, Secondary; Rotenone; Ubiquinone; Uncoupling Agents | 2003 |
Glutamatergic drugs in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Excitatory Amino Acid Antagonists; Humans; Parkinson Disease; Parkinson Disease, Secondary; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate | 1994 |
Metabolic aspects of the behavior of MPTP and some analogues.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Humans; Monoamine Oxidase; Parkinson Disease, Secondary; Pyridinium Compounds; Structure-Activity Relationship; Substantia Nigra | 1993 |
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Mitochondrial mechanisms of neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Brain; Cell Death; Disease Models, Animal; Humans; Mitochondria; MPTP Poisoning; Neurons; Neurotoxins; Parkinson Disease, Secondary | 1992 |
MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Blood-Brain Barrier; Cell Survival; Drug Contamination; Humans; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds | 1987 |
1 trial(s) available for 1-methyl-4-phenylpyridinium and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline | 1985 |
89 other study(ies) available for 1-methyl-4-phenylpyridinium and Parkinson Disease, Secondary
| Article | Year |
|---|---|
TGR5 Agonist INT-777 Alleviates Inflammatory Neurodegeneration in Parkinson's Disease Mouse Model by Modulating Mitochondrial Dynamics in Microglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cholic Acids; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Microglia; Mitochondrial Dynamics; Parkinson Disease, Secondary; Tumor Necrosis Factor-alpha | 2022 |
Silencing of TRIM10 alleviates apoptosis in cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Down-Regulation; Dual Specificity Phosphatase 6; Gene Knockdown Techniques; Intracellular Signaling Peptides and Proteins; Oxidative Stress; Parkinson Disease, Secondary; PC12 Cells; Rats; Tripartite Motif Proteins; Up-Regulation | 2019 |
ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Amides; Animals; Apoptosis; Dopamine; Dopaminergic Neurons; Dynamins; Gene Expression Regulation; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitochondrial Dynamics; Oxidative Stress; Parkinson Disease, Secondary; PC12 Cells; Pyridines; Rats; rho-Associated Kinases; Signal Transduction; Substantia Nigra | 2019 |
Neuroprotection of Indole-Derivative Compound NC001-8 by the Regulation of the NRF2 Pathway in Parkinson's Disease Cell Models.
Topics: 1-Methyl-4-phenylpyridinium; Caspase 3; Cell Line, Tumor; Dopaminergic Neurons; Humans; Indoles; Induced Pluripotent Stem Cells; Models, Neurological; NAD(P)H Dehydrogenase (Quinone); Neuroprotection; NF-E2-Related Factor 2; Parkinson Disease, Secondary; Reactive Oxygen Species; Signal Transduction; Up-Regulation | 2019 |
Photoactivation of ERK/CREB/VMAT2 pathway attenuates MPP
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Cell Survival; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Humans; Low-Level Light Therapy; Neurons; Parkinson Disease, Secondary; Signal Transduction; Vesicular Monoamine Transport Proteins | 2017 |
Protective function of SLC30A10 induced via PERK-ATF4 pathway against 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Activating Transcription Factor 4; Animals; Cation Transport Proteins; Cell Line, Tumor; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Expression Regulation; Humans; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease, Secondary; Protein Isoforms; RNA, Small Interfering; Transcription Factor CHOP; Tunicamycin; Zinc Transporter 8 | 2017 |
Enteric Neurodegeneration is Mediated Through Independent Neuritic and Somal Mechanisms in Rotenone and MPP+ Toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Enteric Nervous System; Female; Insecticides; Mice; MPTP Poisoning; Nerve Degeneration; Neurites; Parkinson Disease, Secondary; Parkinsonian Disorders; Pregnancy; Rotenone | 2018 |
Simultaneous Relative Quantification of Various Polyglycerophospholipids with Isotope-Labeled Methylation by Nanoflow Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deuterium; Humans; Isotope Labeling; Methylation; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylglycerols; Rotenone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Attenuation of Endoplasmic Reticulum Stress, Impaired Calcium Homeostasis, and Altered Bioenergetic Functions in MPP
Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Calcium; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Energy Metabolism; Homeostasis; Humans; Membrane Potential, Mitochondrial; Mitochondria; Parkinson Disease, Secondary; Rutin | 2019 |
MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death.
Topics: 1-Methyl-4-phenylpyridinium; Activating Transcription Factor 3; Animals; Apoptosis Regulatory Proteins; Cell Death; Cells, Cultured; DNA Damage; Dopamine Agents; Genes, p53; Immunohistochemistry; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Chaperones; Parkinson Disease, Secondary; Real-Time Polymerase Chain Reaction; Tumor Suppressor Proteins; Unfolded Protein Response; Up-Regulation | 2013 |
The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Brain; Cells, Cultured; Dopaminergic Neurons; Gene Expression; Humans; Immunoblotting; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Motor Activity; Naphthoquinones; Neurotoxins; NIMA-Interacting Peptidylprolyl Isomerase; Parkinson Disease; Parkinson Disease, Secondary; Peptidylprolyl Isomerase; RNA Interference; RNA-Directed DNA Polymerase; Substantia Nigra; Up-Regulation | 2013 |
Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Calcium; Calcium Channels; Calcium Signaling; Carrier Proteins; Cell Death; Cells, Cultured; Dopamine; Homeostasis; Homer Scaffolding Proteins; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering | 2013 |
Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Cell Death; Cell Differentiation; Cell Line; Cyclin-Dependent Kinase 2; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Humans; Indoles; Maleimides; Mesencephalon; Neurons; Neuroprotective Agents; Parkinson Disease; Parkinson Disease, Secondary | 2014 |
MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Cell Death; Cells, Cultured; Dopaminergic Neurons; Down-Regulation; Humans; Mice; MicroRNAs; Neurons; Neuroprotective Agents; NF-kappa B; Parkinson Disease, Secondary; Substantia Nigra; Transcription Factor RelA; Transfection | 2014 |
Methylmercury can induce Parkinson's-like neurotoxicity similar to 1-methyl-4- phenylpyridinium: a genomic and proteomic analysis on MN9D dopaminergic neuron cells.
Topics: 1-Methyl-4-phenylpyridinium; Cells, Cultured; Dopamine; Dopaminergic Neurons; Energy Metabolism; Genome; Genomics; Humans; Methylmercury Compounds; Neurotoxicity Syndromes; Oxidative Phosphorylation; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Proteome; Proteomics; Signal Transduction; Tyrosine 3-Monooxygenase; Ubiquitin-Conjugating Enzymes | 2015 |
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Benzamides; Diencephalon; Disease Models, Animal; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Indoles; Larva; Locomotion; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Pyridines; RNA, Messenger; Tyrosine 3-Monooxygenase; Xanthenes; Zebrafish; Zebrafish Proteins | 2016 |
Linking Inflammation and Parkinson Disease: Hypochlorous Acid Generates Parkinsonian Poisons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dose-Response Relationship, Drug; Encephalitis; Female; Humans; Hypochlorous Acid; Inflammation Mediators; Male; Mice, Inbred C57BL; Mitochondria; Motor Activity; Parkinson Disease, Secondary; Rats, Inbred BN; Rats, Inbred F344; Substantia Nigra; Time Factors; Tumor Necrosis Factor-alpha | 2016 |
Knockdown of JMJD1C, a target gene of hsa-miR-590-3p, inhibits mitochondrial dysfunction and oxidative stress in MPP+-treated MES23.5 and SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Cell Line; Gene Expression Regulation; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Jumonji Domain-Containing Histone Demethylases; MicroRNAs; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Oxidoreductases, N-Demethylating; Parkinson Disease, Secondary; RNA Interference; RNA, Small Interfering | 2016 |
Mild MPP
Topics: 1-Methyl-4-phenylpyridinium; Acids; Autophagy; Cathepsin D; Cell Death; Cell Line; Dopamine Agents; Humans; Lysosomes; Parkinson Disease, Secondary; Phagosomes; Sirolimus; Trehalose | 2016 |
Neuronal hemoglobin affects dopaminergic cells' response to stress.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autophagy; Brain; Dopaminergic Neurons; Epigenesis, Genetic; Gene Expression; Hemoglobins; Humans; Mice; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Substantia Nigra | 2017 |
Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Adenoviridae; Animals; Brain-Derived Neurotrophic Factor; Cell Death; Cells, Cultured; Coculture Techniques; Dopamine; Enzyme Induction; Glial Cell Line-Derived Neurotrophic Factor; Heme Oxygenase-1; Humans; Interleukin-1beta; Neuroglia; Neurons; Parkinson Disease, Secondary; Rats; Rats, Wistar; RNA, Messenger; Tumor Necrosis Factor-alpha | 2008 |
dl-3-n-Butylphthalide prevents oxidative damage and reduces mitochondrial dysfunction in an MPP(+)-induced cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Antioxidants; Apium; Benzofurans; Cell Survival; Cytoprotection; Glutathione; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Parkinson Disease, Secondary; PC12 Cells; Rats; Reactive Oxygen Species | 2010 |
Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis Regulatory Proteins; Brain; Brain Chemistry; Corpus Striatum; Cyclooxygenase 2; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Frontal Lobe; In Vitro Techniques; Inflammation Mediators; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Parkinson Disease, Secondary; Phospholipases A2, Cytosolic; RNA, Messenger | 2010 |
Impairment of oxidative stress-induced heme oxygenase-1 expression by the defect of Parkinson-related gene of PINK1.
Topics: 1-Methyl-4-phenylpyridinium; Adenoviridae; Benzimidazoles; Blotting, Western; Cell Line; Cell Survival; Cloning, Molecular; Coloring Agents; Dopamine; Fluorescent Antibody Technique; Fluorescent Dyes; Gene Expression Regulation; Genetic Vectors; Heme Oxygenase-1; HSP90 Heat-Shock Proteins; Humans; L-Lactate Dehydrogenase; Mutation; Oxidative Stress; Parkinson Disease, Secondary; Protein Kinases; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tetrazolium Salts; Thiazoles | 2011 |
Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cytokines; Erythropoietin; Granulocyte Colony-Stimulating Factor; Models, Biological; Neuroprotective Agents; Parkinson Disease, Secondary; PC12 Cells; Rats; Tumor Suppressor Protein p53 | 2011 |
PEP-1-heat shock protein 27 protects from neuronal damage in cells and in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell Line, Tumor; Cysteamine; DNA Fragmentation; Dopaminergic Neurons; Escherichia coli; HSP27 Heat-Shock Proteins; Humans; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Parkinson Disease, Secondary; Peptides; Reactive Oxygen Species; Recombinant Fusion Proteins; Rotarod Performance Test; Substantia Nigra | 2012 |
Protection against neurotoxicity by an autophagic mechanism.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apium; Autophagy; Benzofurans; Blotting, Western; Cell Survival; Immunohistochemistry; Microscopy, Electron, Transmission; Neuroprotective Agents; Parkinson Disease, Secondary; PC12 Cells; Rats; Seeds | 2012 |
Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenylpyridinium; Animals; Axons; Behavior, Animal; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Degeneration; Neurites; Neuroprotective Agents; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; rho-Associated Kinases; Substantia Nigra | 2012 |
Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models.
Topics: 1-Methyl-4-phenylpyridinium; Antiparkinson Agents; Cell Differentiation; Cells, Cultured; Dopaminergic Neurons; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; Microarray Analysis; Models, Theoretical; Neurogenesis; Neuroprotective Agents; Parkinson Disease, Secondary; Pluripotent Stem Cells; Rotenone | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environmental Exposure; gamma-Aminobutyric Acid; Gliosis; Herbicides; Homovanillic Acid; Humans; Injections, Intraperitoneal; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Blotting, Western; Carrier Proteins; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Death; Cells, Cultured; Cysteine Endopeptidases; DNA-Binding Proteins; Dopamine; eIF-2 Kinase; Embryo, Mammalian; Embryo, Nonmammalian; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Gene Expression Regulation; Heat-Shock Proteins; Immunohistochemistry; Mesencephalon; Molecular Chaperones; Multienzyme Complexes; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorus Compounds; Proteasome Endopeptidase Complex; Protein Folding; Proto-Oncogene Proteins c-jun; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factor CHOP; Transcription Factors; Ubiquitin | 2003 |
Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cell Line; Cell Survival; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Harmaline; Harmine; Humans; Inhibitory Concentration 50; Kidney; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Methylation; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperazines | 2004 |
The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cattle; Cytoskeleton; Herbicides; Humans; Microtubules; Nerve Degeneration; Neurotoxins; Parkinson Disease, Secondary | 2005 |
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Calpain; Caspase 3; Caspases; Cell Survival; Cells, Cultured; Cerebellum; Cyclin-Dependent Kinase 5; Enzyme Activation; Melatonin; Nerve Tissue Proteins; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2006 |
Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).
Topics: 1-Methyl-4-phenylpyridinium; Animals; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Intraventricular; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Survival Rate | 2006 |
Chemical genomic profiling for identifying intracellular targets of toxicants producing Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Cluster Analysis; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Fungal; Genome, Human; Humans; Insecticides; Oligonucleotide Array Sequence Analysis; Paraquat; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Proteins; Saccharomyces cerevisiae; Sequence Homology, Nucleic Acid; Ubiquitin | 2007 |
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Guinea Pigs; Humans; Macaca mulatta; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats; Saimiri; Species Specificity; Structure-Activity Relationship; Substantia Nigra | 1984 |
Biphasic effects of MPP+, a possible parkinsonism inducer, on dopamine content and tyrosine hydroxylase mRNA expression in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Neurons; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 1995 |
Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+.
Topics: 1-Methyl-4-phenylpyridinium; Aged; Amino Acids; Animals; Biogenic Monoamines; Female; Homovanillic Acid; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 1994 |
1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Aurintricarboxylic Acid; Bucladesine; Cycloheximide; L-Lactate Dehydrogenase; Nerve Growth Factors; Parkinson Disease, Secondary; PC12 Cells; Potassium; Rats | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Homovanillic Acid; Male; Parkinson Disease, Secondary; Rats; Riluzole; Thiazoles | 1994 |
[Role of the striatal serotoninergic apparatus in Parkinsonian syndrome].
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antigen-Antibody Reactions; Corpus Striatum; Parkinson Disease, Secondary; Rabbits; Rats; Serotonin | 1993 |
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electroencephalography; Male; Neostigmine; Neurons; Oxotremorine; Parkinson Disease, Secondary; Rats; Receptors, Cholinergic; Substantia Nigra | 1993 |
Neurotoxicity of nicotinamide derivatives: their role in the aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Humans; Isomerism; Kinetics; L-Lactate Dehydrogenase; Neuroblastoma; Neurotoxins; Niacinamide; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rotenone; Tumor Cells, Cultured | 1993 |
Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Base Sequence; Biological Transport; Carrier Proteins; Cell Line; Cell Survival; Chlorocebus aethiops; CHO Cells; Cloning, Molecular; Cricetinae; DNA Primers; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Kidney; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Molecular Sequence Data; Nerve Tissue Proteins; Neuroblastoma; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synaptosomes; Transfection; Tumor Cells, Cultured | 1993 |
Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell Division; Dopamine; Dopamine Agents; Glial Cell Line-Derived Neurotrophic Factor; Mesencephalon; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 1996 |
[Effect of active immunization with a serotonin-protein conjugate on development of experimental Parkinson's syndrome].
Topics: 1-Methyl-4-phenylpyridinium; Animals; Male; Parkinson Disease, Secondary; Rats; Rats, Wistar; Serotonin; Serum Albumin, Bovine; Vaccination | 1996 |
Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Biological Transport, Active; Cattle; Neurotoxins; Parkinson Disease, Secondary; PC12 Cells; Rats | 1996 |
Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dopamine; Lactic Acid; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Norepinephrine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synaptosomes | 1997 |
The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autoradiography; Brain; Dopamine Agents; Immunohistochemistry; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Neurons; Neuropeptides; Neurotoxins; Parkinson Disease, Secondary; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Benzothiazoles; Biological Transport; Calcium; Corpus Striatum; Dopamine Agents; Humans; Ion Channel Gating; Liver; Male; Microdialysis; Mitochondria; Neuroblastoma; Neuroprotective Agents; Neurotoxins; Parkinson Disease, Secondary; Phosphorus; Porins; Pramipexole; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured | 1998 |
Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carrier Proteins; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Heterocyclic Compounds; In Vitro Techniques; Kinetics; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Neostriatum; Nerve Tissue Proteins; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Wistar; Species Specificity; Synaptosomes | 1998 |
Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Cerebellum; Cysteine Proteinase Inhibitors; Cytochrome c Group; DNA Fragmentation; Dopamine Agents; Mitochondria; Neurons; Oligopeptides; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sympatholytics | 1999 |
Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Biogenic Amines; Carbolines; Haloperidol; Harmine; Isoquinolines; Male; Mitochondria; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 1999 |
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; DNA Damage; Enzyme Activation; Immunohistochemistry; Mice; Mice, Knockout; Monoamine Oxidase; Nitric Oxide Synthase; Nuclear Proteins; Parkinson Disease, Secondary; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Substantia Nigra | 1999 |
Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Hydroxybenzoates; Hydroxyl Radical; Iron Chelating Agents; Male; Parkinson Disease, Secondary; Rats; Rats, Wistar; Reserpine; Salicylic Acid; Sympatholytics | 1999 |
The D-loop structure of human mtDNA is destabilized directly by 1-methyl-4-phenylpyridinium ion (MPP+), a parkinsonism-causing toxin.
Topics: 1-Methyl-4-phenylpyridinium; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; DNA, Mitochondrial; DNA, Single-Stranded; DNA, Superhelical; HeLa Cells; Hot Temperature; Humans; Hydrogen-Ion Concentration; Kinetics; Mitochondria; Nucleic Acid Conformation; Nucleic Acid Denaturation; Parkinson Disease, Secondary; Potassium Iodide; Recombinant Proteins | 2000 |
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Electron Transport Complex II; Energy Metabolism; Glucose; Herbicides; Humans; Isoquinolines; Mitochondria; Multienzyme Complexes; NAD; NADH, NADPH Oxidoreductases; Neuroblastoma; Oxidoreductases; Parkinson Disease, Secondary; Rotenone; Succinate Dehydrogenase; Tumor Cells, Cultured; Uncoupling Agents | 2000 |
Potassium chloride depolarization enhances MPP+-induced hydroxyl radical generation in the rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Cyclooxygenase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Herbicides; Hydroxyl Radical; Iron; Male; Membrane Potentials; Microdialysis; Parkinson Disease, Secondary; Potassium Chloride; Rats; Rats, Wistar; Sodium Salicylate | 2000 |
MPP(+)-induced mitochondrial dysfunction is potentiated by dopamine.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Drug Synergism; In Vitro Techniques; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; NADH Dehydrogenase; Nerve Degeneration; Neurotoxins; Oxygen Consumption; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2000 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indazoles; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole | 2000 |
Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Estrogens; Extracellular Space; Female; Herbicides; Male; Microdialysis; Nerve Degeneration; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sex Characteristics | 2000 |
Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Electron Transport Complex I; Humans; In Vitro Techniques; Melatonin; Mitochondria; Mitochondria, Liver; NADH, NADPH Oxidoreductases; Oxidative Stress; Oxygen Consumption; Parkinson Disease, Secondary; Rats; Synaptosomes | 2000 |
Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caspase 1; Caspase 3; Caspases; Cell Line; Dopamine; Dose-Response Relationship, Drug; Hydrogen Peroxide; Lethal Dose 50; Mice; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Neurons; Neurotoxins; Oxidants; Parkinson Disease, Secondary; Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Tyrosine 3-Monooxygenase | 2001 |
Allopurinol suppresses para-nonylphenol and 1-methyl-4-phenylpyridinium ion (MPP(+))-induced hydroxyl radical generation in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Allopurinol; Animals; Dose-Response Relationship, Drug; Drug Interactions; Free Radical Scavengers; Hazardous Substances; Hydroxyl Radical; Male; Microdialysis; Neostriatum; Nerve Degeneration; Parkinson Disease; Parkinson Disease, Secondary; Phenols; Rats; Rats, Wistar | 2001 |
GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+ -induced apoptosis.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Survival; Cells, Cultured; Dopamine; Fetus; Glyceraldehyde-3-Phosphate Dehydrogenases; Herbicides; Immunohistochemistry; Microtubule-Associated Proteins; Neurons; Oligonucleotides, Antisense; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Macaca fascicularis; Male; Nerve Degeneration; Neurons; Parkinson Disease, Secondary; Putamen; Substantia Nigra | 1992 |
Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carrier Proteins; Cell Line; DNA; Dopamine Plasma Membrane Transport Proteins; Kidney; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neurotoxins; Parkinson Disease, Secondary | 1992 |
Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Chromatography, High Pressure Liquid; Gas Chromatography-Mass Spectrometry; Haloperidol; Male; Mice; Microsomes, Liver; Parkinson Disease, Secondary | 1991 |
Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Corpus Striatum; Humans; Mice; Parkinson Disease; Parkinson Disease, Secondary; Rats; Tyrosine 3-Monooxygenase | 1990 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Autoradiography; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Female; Fetal Tissue Transplantation; Immunohistochemistry; Injections; Methamphetamine; Neural Pathways; Parkinson Disease, Secondary; Pregnancy; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1990 |
[Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Female; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Time Factors | 1990 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Limbic System; Mice; Motor Activity; Neurotransmitter Agents; Norepinephrine; Parkinson Disease, Secondary; Phenethylamines; Pyridinium Compounds; Selegiline; Serotonin | 1985 |
A sheep model for MPTP induced Parkinson-like symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; Female; Parkinson Disease, Secondary; Sheep | 1989 |
Visualization of interleukin-2-like molecules in MPP(+)-lesioned rat brain.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autoradiography; Brain; Brain Chemistry; Interleukin-2; Male; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Interleukin-2 | 1989 |
[Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; Lipid Peroxidation; Male; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats | 1989 |
[Clinico-electroencephalographic indices of the parkinsonian syndrome induced by MPP+ in rats].
Topics: 1-Methyl-4-phenylpyridinium; Animals; Electrodes, Implanted; Electroencephalography; Male; Motor Activity; Neurotoxins; Parkinson Disease, Secondary; Pyridinium Compounds; Rats; Time Factors | 1989 |
[Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Corpus Striatum; Disease Models, Animal; Humans; Monoamine Oxidase Inhibitors; Neural Pathways; Neuronal Plasticity; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Pyridinium Compounds; Receptors, Dopamine; Substantia Nigra; Synapses; Synaptic Transmission | 1986 |
N-methyl-4-phenylpyridine (MMP+) together with 6-hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calcium; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Dopamine; Egtazic Acid; Female; Hydroxydopamines; In Vitro Techniques; Mitochondria; NAD; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats; Rats, Inbred Strains | 1986 |
Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; Dopamine; Haplorhini; Mice; Monoamine Oxidase; Neurotoxins; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Spinal Cord | 1987 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Female; Functional Laterality; Methamphetamine; Parkinson Disease, Secondary; Posture; Pyridinium Compounds; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1988 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autoradiography; Benzazepines; Corpus Striatum; Functional Laterality; Image Processing, Computer-Assisted; Male; Parkinson Disease, Secondary; Pyridinium Compounds; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Receptors, Dopamine; Sincalide; Spiperone; Substantia Nigra | 1988 |
Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Brain Chemistry; Male; Monoamine Oxidase; Neurotoxins; Oxidation-Reduction; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats; Rats, Inbred Strains | 1986 |
Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adult; Animals; Brain; Dopamine; Free Radicals; Humans; Male; Melanins; Monoamine Oxidase; Norepinephrine; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds | 1987 |
Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenyl-pyridinium ion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Electrons; Humans; Kinetics; Neurotoxins; Oxidation-Reduction; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds | 1987 |
Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Brain; Humans; Mitochondria; Monoamine Oxidase; NAD; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats | 1987 |
New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Catecholamines; Disease Models, Animal; Melanophores; Motor Activity; Movement; Pargyline; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Pyrogallol; Ranidae; Reflex; Salamandridae; Skin Pigmentation | 1985 |
Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adrenal Medulla; Animals; Behavior, Animal; Brain Chemistry; Dopamine; Drug Interactions; Epinephrine; Melanophores; Motor Activity; Norepinephrine; Paraquat; Pargyline; Parkinson Disease, Secondary; Pigmentation; Posture; Pyridines; Pyridinium Compounds; Rana pipiens; Reflex | 1985 |
1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cytochrome Reductases; Glutathione Reductase; NADH Dehydrogenase; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Spectrophotometry | 1985 |